Inconsistent islet isolation is one of the issues of clinical islet transplantation. In the current study, we applied ductal injection to improve the consistency of islet isolation. Seven islet isolations were performed with the ductal injection of ET-Kyoto solution (DI group) and eight islet isolations were performed without the ductal injection (standard group) using brain-dead donor pancreata. Isolated islets were evaluated based on the Edmonton protocol for transplantation. The DI group had significantly higher islet yields (588,566 ± 64,319 vs. 354,836 ± 89,649 IE, p < 0.01) and viability (97.3 ± 1.2% vs. 92.6 ± 1.2%, p < 0.02) compared with the standard group. All seven isolated islet preparations in the DI group (100%), versus only three out of eight isolated islet preparations (38%) in the standard group met transplantation criteria. The islets from the DI group were transplanted into three type 1 diabetic patients and all three patients became insulin independent. Ductal injection significantly improved quantity and quality of isolated islets and resulted in high success rate of clinical islet transplantation. This simple modification will reduce the risk of failure of clinical islet isolation.
INTRODUCTION
ness of this technique. We demonstrated that introduction of pancreatic ductal injection enabled us to achieve seven consecutive successful clinical islet isolations. Failure to consistently obtain a high quantity and quality of islets is one of the major obstacles for clinical islet transplantation. Even advanced islet centers barely MATERIALS AND METHODS achieved 50% success of clinical islet isolations (1, 2, 4) .
Ethical Guidelines Recently we demonstrated that our modification of the Ricordi islet isolation method enabled us to achieve This study was approved by the institutional review boards and the application of investigational new drug more than 80% success rate of clinical islet isolation with non-heart-beating donors (NHBDs) (6,10). This of clinical islet transplantation is approved by U.S. Food and Drug Administration. modified islet isolation method consists of rapid cooling of the pancreas after cardiac arrest, ductal preservation Donor Background with modified Kyoto solution, two-layer pancreas preservation, Ricordi method for pancreas digestion, and Donor selections were performed based on the Edmonton protocol for clinical-grade pancreas (16) . Seven density-adjusted continuous islet purification with iodixanol and Kyoto solution (5) . In this study, among those pancreata from BDDs were procured through either Southwest Transplant Alliance (Dallas, TX) or LifeGift procedures, we introduce pancreatic ductal injection for brain-dead donors (BDDs) in order to clarify the useful-(Fort Worth, TX) between February 2007 and May 2008 for the ductal injection (DI) group. For historical con-number of islet equivalents (IE, diameter standardizing to 150 µm) (5, 7, 12) . Purity was assessed by comparing trol, eight pancreata from BDDs were procured through Southwest Transplant Alliance (Dallas, TX) between the relative quantity of dithizone-stained tissue to unstained exocrine tissue . Islet viability was evaluated us-April 2005 and December 2006. ing fluorescein diacetate (FDA) and propidium iodide Pancreata Procurement, Islet Isolation, (PI) staining to visualize live and dead cells simultaneand Purification ously (5, 7, 12) . All pancreata were procured by transplant surgeons Islet Transplantations Into Type 1 Diabetic Patients of Baylor Regional Transplantation Institute (Dallas & Once islet preparations met the criteria of the Edmon-Fort Worth, TX). For the DI group, we removed the ton protocol for transplantation, those isolations were duodenum and spleen from the pancreas at the procureconsidered successful. Our current criteria for the apment site. This process was performed by the Baylor proval of clinical transplantation are that islet yields are islet team. A cannula was immediately inserted into the more than 4000 IE/kg body weight, purity more than procured pancreas through the main pancreatic duct 30%, viability more than 70%, tissue volume less than from the direction of the pancreatic head. Approxi-10 ml, endotoxin level less than 5 EU/kg body weight, mately 1 ml/g pancreas of ET-Kyoto solution (Otsuka and a negative Gram stain based on the Edmonton proto-Pharm Factory Inc., Naruto, Japan) was administered incol (16) . traductally (5, 6, 10) . For the standard group, the ductal Recipient selections were performed based on the Edinjection process was not performed. All pancreata in monton protocol (16) . Patients were sedated and a perboth the DI group and the standard group were precutaneous transhepatic approach was used to gain access served by the oxygen static charged two-layer (oxygento the portal vein for all patients. Once access was conated perfluorocarbon/UW solution) method for less than firmed, the Seldinger technique was used to place the 6 h (8).
Kumpe catheter within the main portal vein. Islets were Islet preparations were performed according to Good infused by gravity and using the bag technique (6). Manufacturing Practice (GMP) at the Baylor Research Institute cell processing facility in Dallas, Texas. Islet Assessment of Transplanted Islet Function isolation was performed according to the Ricordi Islet functioning was assessed in terms of daily serum method using the same standard operation procedure glucose levels, serum C-peptide, amount of insulin re- (13) . Briefly, after the pancreas was decontaminated, the quirement, and HbA 1C before and after islet transplantaduct was perfused in a controlled fashion with a cold tion. enzyme solution. Liberase HI (Roche Molecular Biochemicals, Indianapolis, IN) was used for two cases of Statistic Analysis the DI group and all cases of the standard groups. Colla-Values for the data collected represent means ± SE. genase NB with neutral proteases (Serva Electrophoresis Two groups were compared using unpaired t-test. Ratio GMbH, Heidelberg) was used for the remaining five between two groups was compared using Fisher's exact cases of the DI group. The distended pancreas was then test. Values of p < 0.05 were considered significant. cut into pieces and transferred to a Ricordi chamber. The pancreas was digested by repeatedly circulating the en-RESULTS zyme solution through the Ricordi chamber at 37°C. The Donor and Islet Characteristics phase I period was defined as the time between placement of the pancreas in the Ricordi chamber and the Donor-related variables were shown in Table 1 . There were no significant differences in the ratio of gen-start of collection of the digested pancreas. The phase II period was defined as the time between the start and the der, age, body mass index, peak blood levels of glucose, alanine aminotransferase (ALT), and creatinine. end of the collection.
The islets were purified with a continuous density Islet isolation variables were shown in Table 2 . There were no significant differences in pancreas weight, cold gradient using Biocoll in a chilled apheresis system (COBE 2991 cell processor, Gambro Laboratories, Den-ischemic time, phase I period, and undigested tissue volume. All pancreata were preserved less than 6 h. Phase ver, CO) (7,14).
II period was significantly longer in the DI group.
Islet Evaluation
Prepurification islet yield was significantly higher in the DI group (DI vs. standard: 902,350 ± 139,397 vs. Islet evaluation was independently judged by two investigators. Islet yield was determined using dithizone 497,457 ± 89,414 IE; p < 0.03) ( Fig. 1, right) . After islet purification, islet yields were also significantly higher staining (Sigma Chemical Co., St. Louis, MO) (2 mg/ ml) under optical graticule and converted into a standard in the DI group (DI vs. standard: 588,566 ± 64,319 vs. 354,836 ± 89,649 IE; p < 0.01) ( Fig. 1 left) . Islet vari-transplantation were 6.0%, 5.8%, and 5.8%, respectively. Fasting C-peptide levels were all undetectable be-ables are shown in Table 3 . Viability was significantly higher in the DI group. Purity was significantly lower in fore transplantation. The current fasting C-peptide for the first patient was 2.2 ng/dl, 3.2 ng/dl for the second the DI group. patient, and 2.1 ng/dl for the third patient.
Success of Islet Isolation
DISCUSSION All isolated islet preparations were qualified for transplantation in the DI group (Table 4 ). Three out of To our knowledge, this is the first study of pancreatic ductal injection at the donor site for clinical islet trans-eight isolated islet preparations were qualified for transplantation in the standard group; the other five had an plantation using brain-dead donors (BDDs). This modification enabled us to have seven consecutive successful insufficient islet yield. We attempted to transplant all seven islet preparations in the DI group, but in one case clinical islet isolations. Failure of islet isolation is one of the major issues for clinical islet transplantation be-the radiologist could not gain access to portal vein and the preparation was not transplanted. Therefore, only six cause of the loss of donor pancreas, waste of money and efforts (3) . Therefore, this simple modification is of preparations were transplanted into three type 1 diabetic patients. Each patient received two islet preparations. In great value for clinical islet transplantation.
Previously we have shown that modification of the the standard group, two successful preparations were transplanted into two type 1 diabetic patients. The other Ricordi method including ductal injection improved islet yields using NHBDs (6,10). For NHBDs, we used ET-one case was not transplanted due to lack of full preparation in clinical side.
Kyoto solution combined with ulinastatin (6,10); however, we eliminated ulinastatin for this study because Clinical Outcome in the DI Group ulinastatin is not available in the US. In addition, usefulness of trypsin inhibition for BDDs is controversial In the DI group, fasting blood glucose of all three patients improved after single islet transplantation and (9,14). In this study, we confirmed that the ET-Kyoto solution alone was effective for ductal preservation for further improved after the second islet transplantation (Fig. 2) . Importantly, after the second islet transplanta-BDDs.
Recently we have shown that more than 10% of exo-tion, no patients experienced severe hypoglycemia thereafter.
crine tissue suffered apoptic cell death during preservation before islet isolation and the ductal injection of All three patients became insulin independent (Fig.  3) . HbA 1C before transplantation was 8.3% (first patient), modified Kyoto solution reduced exocrine tissue apoptosis to less than 2% in the porcine model (11). In addi-8.3% (second patient), and 7.4% (third patient) and after tion, the ductal injection with both UW solution and could be important to prevent overdigestion of isolated islets. It is reasonable to think that the ductal injection modified Kyoto solution improved ATP activity in the cellular component in a porcine model (11). However, prevents exocrine cell death and therefore avoids overdigestion of isolated islets. Low purity of isolated islets UW solution inhibits collagenase activity for human pancreas (11), and therefore we chose ET-Kyoto solu-can be a concern because a lower purity results in a larger tissue volume. The tissue volume was higher in tion for human islet isolation. Importantly, phase I time and undigested tissue volume was not different between the DI group, although the difference did not reach statistical significance. However, all islet preparations were the DI group and the standard group, suggesting that ductal injection of ET-Kyoto solution did not inhibit the adjusted to less than 10 ml and we had no transplant complications related to relatively large tissue volume. collagenase activity during human pancreas digestion.
Purity was significantly lower in the DI group. We Viability of isolated islets was significantly higher in the DI group. Previously we have shown that DI pre-speculated that the healthier exocrine tissue survived well during the islet isolation process, causing lower pu-vented both exocrine tissue and islets from apoptotic cell death in a porcine model (11). This suggested that DI rity of islet preparations. In addition, significant prolonged phase II time in the DI group suggested that also improved the quality of isolated islets. Sawada et al. demonstrated that the ductal injection healthier exocrine tissue had less autolysis, resulting in a prolonged collection period. Because autolyzed exocrine of small amount of UW solution protected pancreatic duct in rodent model (15). This is another important tissues release several digestive enzymes, less autolysis demonstration of the usefulness of ductal injection because it is essential to maintain good patency of pancre- atic duct for collagenase delivery. Ductal preservation at cause the pancreas is not cut, there is excellent pancreas distension and minimal collagenase leaking. the procurement site allows us to maintain the patency of the pancreatic duct during preservation and transport;
In this study, we lost approximately 35% of islets during the purification process. Previously, we used den-it is therefore possible to use only one cannula for collagenase delivery. The single cannulation technique is sity-adjusted ET-Kyoto and iodixanol solution for purification with NHBDs, resulting in approximately 80% better than the usual two cannulations because this technique eliminates cutting pancreas for cannulation. Be-recovery rate (6). If we were able to achieve the same recovery rate with BDDs, we might be able to obtain All three transplanted patients in the DI group became insulin independent after the second infusion, and more than 700,000 IE from a single donor. Currently 10,000 IE/kg recipient body weight is the target for insu-have improved glycemic control with positive C-peptide. All patients are free from severe hypoglycemia. This lin independence (16) ; therefore, this high yield would enable us to perform single donor islet transplantation clinical outcome shows that DI is not only useful for obtaining high islet yields but is also contributing to the in patients up to 70 kg body weight. Introduction of density-adjusted ET-Kyoto and iodixanol solution for puri-high quality of islets. We compared with our own historical data to demon-fication is currently under investigation at our laboratory.
strate the impact of introduction of a new strategy. Strictly 
